Evvy, a women’s health startup founded in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, has raised $40 million in a Series B funding round led by Catalio Capital Management. With a mission to bring clarity to women’s health, the company leverages advanced vaginal microbiome data to improve diagnostics, treatment personalization, and health outcomes.
How Evvy Works & What’s New
Evvy offers what it describes as the first at-home metagenomic next-generation sequencing (mNGS) test for vaginal microbiomes that holds both CLIA and CLEP certifications. Users collect a swab sample at home and mail it to Evvy’s lab. The company runs its proprietary sequencing, clinicians review the results, then users receive findings—including diagnoses, clinical interpretations, and treatment suggestions—through a patient health portal.
Scale, Data & Emerging Insights
To date, Evvy has served over 100,000 patients across the U.S., partnering with more than 3,000 healthcare practitioners. The company has published 15 peer-reviewed papers and abstracts, delineated new subtypes of bacterial vaginosis (BV), and catalogued hundreds of previously unrecognized vaginal microbiome genomes. These datasets allow clinicians to tailor treatment pathways with greater precision than traditional one-size-fits-all approaches.
Beyond treating individuals, Evvy aims to build a comprehensive dataset mapping microbiome biology to symptoms, interventions, and long-term outcomes. This deeper linkage of biological signals—molecular, hormonal, microbiological—with clinical symptomatology and treatment effects is intended to fuel better care and new biomarker discoveries.
AI, Fertility & The Road Ahead
This past May, Evvy launched “EvvyAI,” a digital assistant that translates its microbiome data into immediate health insights. The tool offers real-time guidance and flags issues for clinician input when needed. Meanwhile, the startup has entered the fertility space. It’s actively studying how variations in vaginal microbiomes correlate with infertility, preterm birth, IVF success rates, gynecological cancer, pregnancy loss, and risks associated with HPV—all with the goal of bolstering predictive and preventive models in women’s reproductive health.
Long term, Evvy envisions developing an updated version of a Pap smear: an at-home, non-invasive test that could regularly detect risks across infections, inflammation, PCOS, endometriosis, HPV progression, and menopause. Current industry counterparts include Juno Bio, Tiny Health, and Daye, signaling increasing competition but also shared momentum in the vaginal health field.
Evvy’s leadership underscores the gap in precision medicine: most datasets have historically underrepresented female biology, limiting diagnostic and treatment advances. The new funding will help Evvy expand its dataset, drive deeper clinical research, and strengthen its AI tools to move the industry beyond ambiguous diagnoses in women’s health.
